Journal of Medicinal Chemistry

© Copyright 1985 by the American Chemical Society

Volume 29, Number 1

January 1986


Stereoselective Syntheses of the *trans*-Decahydroquinoline-5-carboxylic Acid Epimers. Diastereomeric Zwitterionic Probes of γ -Aminobutyric Acid Related Biological Properties in Vitro and in Vivo

Donald T. Witiak,*[†] Raymond J. Patch,[†] S. J. Enna,[‡] and Yiu K. Fung[§]

Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, Departments of Pharmacology and of Neurobiology and Anatomy, The University of Texas, Health Science Center at Houston, Houston, Texas 77025, and Department of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Lincoln, Nebraska 68583. Received May 6, 1985

The syntheses of the 5β and 5α epimers of trans-($4\alpha\alpha$, $8\alpha\beta$)-decahydroquinoline-5-carboxylic acids (3 and 4) from vinylogous bicyclic imide 10 are described. The reduction of trans-5-(1,3-dithian-2-ylidene)octahydro-2(1H)-quinolinone (13) to afford the 5α -(1,3-dithian-2-yl) compound 16 was a key step in the synthesis of trans-4 while hydroboration-H₂O₂ treatment of phenylmethyl trans-octahydro-5-methylene-1(2H)-quinolinecarboxylate (21) to afford the 5β hydroxymethyl compound 22 was a key step in the synthesis of 3. These trans diastereomers 3 and 4 and the previously prepared cis analogues 1 and 2 were investigated for their ability to interact with GABA_A and GABA_B receptors and picrotoxin binding sites as well as with neuronal GABA transport systems in brain tissue. Like 1 and 2, tonic-clonic seizures were induced when trans-3 or -4 were administered to mice intracerebroventricularly. Only trans-4 weakly inhibited [³H]GABA binding to GABA_A and GABA_B receptors in vitro. Large doses (10 mg/kg) of diazepam reversed the convulsant activity of both trans-3 and trans-4. Although trans-3 is the more potent convulsant, trans-4 may have GABA antagonist activity in vivo. However, none of the decahydroquinoline diastereomers have a pronounced effect on GABA receptors that can currently be studied in vitro. Results obtained in vivo lead us to propose that these diastereoisomers may serve as unique conformational probes relating certain zwitterionic topographies to stimulatory activity in the central nervous system.

Diastereomeric decahydroquinoline-5-carboxylic acids (1-4) may be viewed as having centrally positioned GABA moieties each contained by two 1,3-propylene functions forming two six-membered rings of the bicyclic system. Given the flexible nature of the cis diastereomers 1 and 2 and the constrained conformations of the trans compounds 3 and 4. these substances serve as unique central nervous system (CNS) conformational probes for stereostructure-activity analysis of a rich variety of zwitterionic topographies of amino and carboxylic acid functions. owing to the lipophilic properties and steric bulk of the propylene units positioned about the GABA pharmacophore, we previously proposed that 1-4 should not be expected to possess the intrinsic activities of GABA receptor agonists but may retain affinity for other GABA receptors/recognition sites thereby serving as stereoselective receptor antagonists or inhibitors of GABA uptake.2,3



[†]The Ohio State University.

However, few of the known selective GABA-uptake inhibitors⁴ can be formally considered as structural GABA analogues. Thus, (R)-(-)-nipecotic acid (5) and guvacine (6), which contain the β -alanine (or δ -aminovaleric acid) relationship of amino and carboxylic acid groups, are among the more potent inhibitors of neuronal and glial GABA uptake.⁵ Cyclic GABA analogues of the type 7⁶ and 8⁷(n = 1-4) did not significantly inhibit GABA uptake at concentrations up to 100 μ M; however, the cyclopropyl


- A preliminary account of the chemistry of this series has been presented to the Division of Medicinal Chemistry, 188th National Meeting of the American Chemical Society, Philadelphia, PA. Patch, R. J.; Witiak, D. T., MEDI-108, 1984. This article was abstracted in part from a dissertation (1984) presented by R.J.P. to The Ohio State University.
- (2) Witiak, D. T.; Tomita, K.; Patch, R. J.; Enna, S. J. J. Med. Chem. 1981, 24, 788-794.
- (3) Fung, Y. K.; Bero, C.; Dircks, D.; Tomita, K.; Patch, R. J.; Witiak, D. T. Res. Commun. Chem. Pathol. Pharmacol. 1983, 39, 367-380.
- (4) By "selective GABA-uptake inhibitors" we are referring to compounds that irrespective of their mechanism inhibit GABA uptake while exhibiting no significant affinity for GABA receptors. A recently published article of interest is Ali, F. E.; Bondinell, W. E.; Dandridge, P. A.; Frazee, J. S.; Garvey, E.; Girard, G. R.; Kaiser, C.; Ku, T. W.; Lafferty, J. J.; Monsammy, G. I.; Oh, H.-J.; Rush, J. A.; Setler, P. E.; Stringer, O. D.; Venslavsky, J. W.; Volpe, B. W.; Yunger, L. M.; Zirkle, C. L. J. Med. Chem. 1985, 28, 653-660.
- (5) Schousboe, A. In "Advances in Experimental Medicine and Biology, GABA—Biochemistry and CNS Functions"; Mandel, P., DeFeudis, F. V., Eds.; Plenum Press: New York, 1979; Vol. 123, pp 219-237.
- (6) Kennewell, P. D.; Matharu, S. S.; Taylor, J. B.; Westwood, R.; Sammes, P. G. J. Chem. Soc., Perkin Trans 1 1982, 2553–2562.
- (7) Kennewell, P. D.; Matharu, S. S.; Taylor, J. B.; Westwood, R.; Sammes, P. G. J. Chem. Soc., Perkin Trans 1 1982, 2563–2570.

0022-2623/86/1829-0001\$01.50/0 © 1985 American Chemical Society

[†]The University of Texas.

[§]University of Nebraska Medical Center.

and cyclobutyl compounds of these series were stereoselective inhibitors of GABA binding to rat brain membranes.⁶⁻⁹ Similar stereoselective activity was observed with structural analogues of the type 9 (n = 1-3).¹⁰ Thus, the corresponding cyclobutyl compounds have little effect on GABA uptake but have good affinity for GABA receptors in brain membranes. On the other hand, the cyclohexyl compound, namely *cis*-3-aminocyclohexanecarboxylic acid (9, n = 3), selectively inhibited GABA uptake into rat brain slices (IC₅₀ = 85 μ M) and is 10 times as potent as the trans isomer in this regard.¹⁰



The preferred solution conformation of cis-9 (n = 3) is thought to be that in which the zwitterionic centers are equatorial rather than axial.¹¹ However, since neither the cyclohexane nor the piperidine ring constitute a conformationally constrained system, solution conformations of 5 or 9 (n = 3) do not necessarily reflect their pharmacologically active orientations. The topography of the GABA pharmacophore found in diequatorial 9 (n = 3) is mimicked in decahydroquinolines cis-2a and trans-4, whereas the diaxial conformation of 9 (n = 3) is mimicked by cis-2b. Of particular interest is trans-4, since this structure constitutes a rigid analogue of diequatorial cis-9 (n = 3). Of course, rigid isomer trans-3 mimicks one possible conformation of trans-9 (n = 3) also found in 1b.

We report in this article the synthesis of trans diastereomers 3 and 4 and the results of a comparative biological evaluation of these substances in conjunction with additional studies of the previously synthesized cis isomers 1 and $2.^2$ The four isomers (1–4) were assessed in vitro for their ability to interact with rat brain GABA_A¹² and GABA_B¹³ receptors, to affect isoproterenol-stimulated and baclofen-enhanced cyclic AMP formation,^{14,15} to inhibit [³H]GABA uptake into rat brain synaptosomes,¹⁶ to affect [³H]diazepam binding and GABA-activated diazepam binding,¹⁷ and to inhibit *tert*-butyl[³⁵S]bicyclophosphorothioate (TBPS) binding.¹⁸ GABA-activated [³H]diazapam binding is a functional measure of GABA_A receptor activity, whereas baclofen-enhanced cyclic AMP formation

- (8) Gardner, C. R.; Roberts, C. J.; Walker, R. J.; Chidley, L.; Clements-Jewery, S. Neuropharmacology 1982, 21, 197-200.
- (9) Allan, R. D.; Curtis, D. R.; Headley, P. M.; Johnston, G. A. R.; Lodge, D.; Twitchin, B. J. Neurochem. 1980, 34, 652–656.
- (10) Johnston, G. A. R.; Allan, R. D.; Kennedy, S. M. E.; Twitchin, B. In "GABA-Neurotransmitters: Pharmacochemical, Biochemical and Pharmacological Aspects"; Krogsgaard-Larson, P., Scheel-Kruger, J., Kofod, H., Eds.; Academic Press: New York, 1979; pp 149–164.
- (11) Hewgill, F. R.; Jefferies, P. R. J. Chem. Soc. 1955, 2767-2772.
- (12) Enna, S. J.; Snyder, S. H. Mol. Pharmacol. 1977, 13, 442-453.
- (13) Hill, D. R.; Bowery, N. G. Nature (London) 1981, 290, 149-152.
- (14) Shimizu, H.; Daly, J. W.; Creveling, C. R. J. Neurochem. 1969, 16, 1609–1619.
- (15) Solomon, Y.; Londos, C.; Rodbell, M. Anal. Biochem. 1974, 58, 541-548.
- (16) Krogsgaard-Larson, P. Mol. Cell Biochem. 1980, 31, 105-121.
- (17) Tallman, J. F.; Thomas, J. W.; Gallager, D. W. Nature (London) 1978, 274, 383-385.
- (18) Squires, R. F.; Casida, J. E.; Richardson, M.; Saederup, E. Mol. Pharmacol. 1983, 23, 326-336.


appears to be a functional measure of GABA_B receptor activity. Additionally, the convulsant effect of trans diastereomers 3 and 4 were investigated following intracerebroventricular (ICV) administration in mice as has been done previously with cis-1 and 2.³

Synthetic Chemistry

The reported syntheses² of cis decahydroquinolines 1 and 2 employed both intra- and intermolecular Diels-Alder reactions as key steps in the reaction sequences. Given the preference for the formation of cis-decahydroquinoline ring systems in these reactions, use of intramolecular Diels-Alder methodology for trans targets 3 and 4 would have required extensive chemical manipulation, such as involvement of a masked carbonyl at position 4 allowing for eventual epimerization. Recognizing complications involved in the epimerization of such systems,¹⁹ we elected to pursue other routes.²⁰ Dissolving-metal reductions of 5,6,7,8-tetrahydroquinolines using sodium in ethanol have been shown to afford trans decahydroquinolines (90%) along with approximately 10% of the corresponding cis isomers.^{21,22} Whereas application of such methodology to the synthesis of decahydroquinoline-5-carboxylic acids might lead to trans-4, lack of stereochemical control at C-5 renders this approach of little use for the synthesis of 3, wherein the epimerizable carboxyl function must assume the thermodynamically less favorable axial position.


A means by which both diastereomers could be stereoselectively prepared was therefore required. To this end we explored preparation of 3 and 4 from *trans*-deca-

- (19) Johnson, R. A.; Murray, H. C.; Reineke, L. M.; Fonken, G. S. J. Org. Chem. 1968, 33, 3207–3217. For 1-benzoyldecahydroquinolin-5-ones the cis ring juncture is thermodynamically more stable, but in closely related decahydroquinolin-4-ones the trans ring juncture is more stable [Mistryukov, E. Izv. Akad. Nauk SSR, Otd, Khim. Nauk 1963, 929]. Johnson et al.¹⁹ have prepared trans-decahydroquinolin-5-one by CrO₃ oxidation of the corresponding 5α -alcohol obtained by microbiological hydroxylation of 1-benzoyl-trans-decahydroquinoline reduction to the benzyl derivative and reductive debenzylation.
- (20) A small sample of trans-3 was prepared from Diels-Alder adduct I (Witiak, D. T.; Tomita, K., unpublished results). Equilibration of I² produced an inseparable mixture (1:2) of isomers I and II, respectively. Wittig reaction afforded the corresponding homologated products III and IV, which upon hydrogenation and reaction with 3,5-dinitrobenzoyl chloride afforded decahydroquinolines V and VI. Isomer trans-V could be separated by preparative TLC and hydrolysis yielded trans-3.




- (a) Me₂SO, 130 °C, 10 h, 90%; (b) Ph₃PCHCHO, 90%; (c) H₂/Pd/C; (d) 3,5-dinitrobenzoyl chloride; (e) chromatography, 6%; (f) HCl, Δ, 53%.
- (21) Vierhapper, F. W.; Eliel, E. L. J. Org. Chem. 1975, 40, 2729-2734.
- (22) Vierhapper, F. W.; Eliel, E. L. J. Org. Chem. 1975, 40, 2734-2742.

Scheme I^a



^a a = 2 equiv of 2-lithio-2-(trimethylsilyl)-1,3-dithiane, THF; b = trifluoroacetic acid, Et₃SiH, 8 days; c = LAH, THF, Δ ; d = CbzCl; e = HgO, BF₃·Et₂O, aqueous THF, Δ ; f = Jones reagent (1.25 MCr⁶⁺); g = H₂, 10% Pd/C, THF/ H₂O·HCl, room temperature, 40 psi, 2 h.

hydroquinoline-2,5-dione (11), which was obtained by reduction of known vinylogous imide 10,²³ constructed by condensation of acrylic acid with 3-amino-2-cyclohexen-1-one by using the method of Shono et al.²⁴ Whereas this method provided a rapid and simple preparation of 10, yields (50–55%) of sufficiently pure product were less than those reported (95%).²⁴



trans-Decahydroquinoline-2,5-dione (11) has previously been obtained²⁵ from an equilibrium mixture of diastereomers, prepared by epimerization of the cis isomer under acidic or basic conditions. In MeOH/MeONa a trans/cis ratio of 58:42 was obtained; in TsOH/benzene the ratio was 45:55. The cis fused system had been obtained in 47.5% overall yield by hydrogenation of 10 over rhodiumalumina catalyst followed by CrO_3 oxidation of the resulting intermediate 12. In these laboratories hydrogen




 (23) Bohme, E. H. W.; Valenta, Z.; Wiesner, K. Tetrahedron Lett. 1965, 2441-2444.
 (24) Shono, T.; Matsumura, Y.; Kashimura, S. J. Org. Chem. 1981.

trong, K.; Imanishi, T. Heterocycles 1979, 12, 393-396.

Momose, T.; Uchida, S.; Miyata, T.; Ohshima, K.; Chiamchit-

46. 3719.

(25)



^a a = Ph₃P⁺CH₂⁻ (2 equiv) THF; b = LAH, THF; c = CbzCl; d = B₂H₆, THF; e = NaOH, H₂O₂; f = ruthenium trichloride hydrate, sodium metaperiodate, ³⁵ CCl₄, CH₃CN, H₂O; g = H₂, 10% Pd/C, THF/H₂O HCl, room temperature, 40 psi, 2 h.

ation of 10 over Pd/C in MeOH containing aqueous KOH afforded a 64:36 mixture of *trans*-11 and its cis diastereomer in yields typically ranging between 70% and 80%. The reaction was carefully monitored to prevent reduction of the ketone. The isomeric ratio was quantified by integration of the H_{8a} proton resonance signal in CDCl₃. For *trans*-11 this signal appears as a deceptively simple doublet of triplets centered at δ 3.27; for the cis isomer this signal occurs as a broad singlet at δ 4.05. Fractional crystallization from H₂O afforded pure *trans*-11.

Peterson olefination²⁶ of trans-11 with 2-lithio-2-(trimethylsilyl)-1,3-dithiane²⁷ (2 equiv) in dry THF afforded ketene dithioacetal 13 in 83% yield (Scheme I). However, hydrolysis to the corresponding carboxylic acids 14 using either HgO/BF₃·Et₂O²⁸ or HgO/HBF₄²⁹ was unsuccessful. Alternatively, the desired compounds were generated in a stepwise process. Reduction of ketene dithioacetal 13 via transfer hydrogenation³⁰ employing trifluoroacetic acid and triethylsilane afforded 16 in 95% yield after 8 days at room temperature. Proton NMR spectroscopy could not be employed for assigning stereochemistry at position 5 of the decahydroquinoline since the H_5 resonance signal is obscured by a 14-proton multiplet which could not be adequately simplified by proton decoupling. Ultimate conversion of 16 to trans-4 coupled with a consideration of the reaction mechanism involving a sulfur-stabilized carbonium ion intermediate³⁰ provided the structural assignment for 16. Thus, the charged dithianyl ring likely assumes the thermodynamically preferred equatorial position of 15 following protonation. Hydride transfer from triethylsilane leads to 16.

Reduction of lactam 16 followed by derivatization afforded Cbz-protected amine 17 in 88% yield. Dethioketalization³¹ was accomplished in 89% yield with use of red mercuric oxide and BF₃·Et₂O in 15% aqueous THF. Jones oxidation of 18 yielded 19 (73%) and hydrogenolysis afforded *trans*-4·HCl (83%).

trans-Decahydroquinoline 11 also served as starting material for the preparation of trans-3 (Scheme II). Wittig reaction employing 2 equiv of methylenetri-

- (27) Corey, E. J.; Seebach, D.; Freedman, R. J. Am. Chem. Soc. 1967, 89, 434-436.
- (28) Corey, E. J.; Beames, D. J. J. Am. Chem. Soc. 1973, 95, 5829-5831.
- (29) Degani, I.; Fochi, R.; Regondi, V. Synthesis 1981, 51-53.
- (30) Carey, F. A.; Court, A. S. J. Org. Chem. 1972, 37, 1926-1929.
- (31) Vedejs, E.; Fuchs, P. L. J. Org. Chem. 1971, 36, 366-367.

⁽²⁶⁾ Peterson, D. J. J. Org. Chem. 1968, 33, 780-784.




Figure 1. NMR spectrum (300 MHz) of $(4a\alpha,5\alpha,8a\alpha)$ -decahydroquinoline-5-carboxylic acid (*cis*-1).




Figure 2. NMR spectrum (300 MHz) of $(4a\alpha,5\beta,8a\alpha)$ -decahydroquinoline-5-carboxylic acid (*cis-2*).

phenylphosphorane in dry THF afforded 20 in a maximum yield of 53%. The yield could not be improved by increasing the length of the reaction time or the amount of ylide used. Reduction and amino group protection afforded carbamate 21 (95%). Diborane reduction of 21, presumably from the least sterically hindered side of the molecule (Dreiding molecular models), provided the stereocontrol necessary for the preparation of target trans-3. Thus, hydroboration $-H_2O_2$ oxidation afforded the axial hydroxymethyl compound 22 in nearly quantitative vield. Interestingly, the bulky reducing agent 9-BBN (9borabicyclo[3.3.1]nonane³²) did not undergo reaction with exocyclic olefin 21. Again, spectral analysis provided no information concerning stereochemistry at position 5 of 22; confirmation of the assigned stereochemistry was obtained by ultimate conversion to trans-3.

Mild oxidative methods were sought for the conversion of 22 to 23 in order to avoid carboxyl group epimerization. Reaction of 22 with pyridinium dichromate in DMF³³ was sluggish; after 2 days and in the presence of excess reagent, the reaction mixture contained substantial quantities of starting alcohol, along with aldehyde and three additional components. Oxidation with ruthenium tetraoxide³⁴ was somewhat more successful in effecting conversion to axial acid 23. No epimerized product was detected in the reaction mixture. Deprotective hydrogenolysis of crude 23 afforded *trans*-3 hydrochloride in 45% overall yield from 22.

¹H NMR Spectroscopy

Proton resonance signal assignments at 90 MHz previously were discussed² for cis-1 and 2. The 300-MHz

- (33) Corey, E. J.; Schmidt, G. Tetrahedron Lett. 1979, 399-402.
 (34) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B.
- J. Org. Chem. 1981, 46, 3936-3938. (35) Substitution of $H_{el}O_{e}$ for NaIO₄ led to a reduced reaction time
- (15 mins) but did not affect the overall yield of this transformation.




Figure 3. NMR spectrum (300 MHz) of $(4a\alpha,5\beta,8a\beta)$ -decahydroquinoline-5-carboxylic acid (trans-3).




Figure 4. NMR spectrum (300 MHz) of $(4a\alpha, 5\alpha, 8a\beta)$ -decahydroquinoline-5-carboxylic acid (trans-4).

spectra are recorded here (Figures 1 and 2, respectively) for comparison with spectra of the trans diastereomers 3 and 4 (Figures 3 and 4, respectively). For trans-4, the axial proton H_5 is strongly coupled to two adjacent axial protons and one equatorial proton. Hence its resonance signal appears as a deceptively simple triplet $(J \simeq 11.2 \text{ Hz})$ of doublets ($J \simeq 3.4 \text{ Hz}$) centered at $\delta 2.06$. A similar pattern was observed for the resonance signal of H_{8a} which also results primarily from two diaxial couplings and one axial-equatorial coupling. This signal appears at δ 2.75 and is partially overlapped by the H_{2ax} resonance signal. The furthest downfield signal (δ 3.20) was assigned to the equatorial proton H_{2eq} resonance signal. The observed doublet, attributed to geminal coupling ($J \simeq 12.8$ Hz), exhibits additional minor splitting and shoulders indicative of quartets. However, these couplings, owing to equatorial-axial and diequatorial interactions were too small to be accurately measured.

Chemical shifts and coupling constants of resonance signals assigned to H_{2eq} and H_{2ax} in trans-3 are essentially the same as those of trans-4. However, H_{8a} , presumably deshielded by the axial carboxylate group, is downfield (δ 3.39) relative to the H_{8a} signal in trans-4. The resonance signal assigned to H_5 having an equatorial conformation also is downfield (δ 2.68) relative to the H_5 axial proton signal in trans-4. This broadened singlet for the H_5 resonance signal in trans-3 reflects relatively smaller equatorial-axial and diequatorial couplings.

Biological Results

The effects of decahydroquinoline-5-carboxylic acids 1–4 on [³H]GABA_A and GABA_B receptor binding to rat brain membranes are shown on Table I. Only *trans*-4 significantly inhibited binding to these receptors, but at 100 μ M the percent displacement of specifically bound [³H]GABA

⁽³²⁾ Brown, H. C.; Krishnamurthy, S.; Yoon, N. M. J. Org. Chem. 1976, 41, 1778–1791.

Table I. Effects of Diastereomeric Decahydroquinoline-5-carboxylic Acids on [³H]GABA_A, [³H]GABA_B, and *tert*-Butyl [³⁵S]Bicyclophosphorothionate (TBPS) Binding in Rat Brain Membranes and [³H]GABA Uptake into Rat Brain Synaptosomes

	% displacem	% inhibn		
compd (100 µM)	[³ H]GABA ^a (GABA _A)	[³ H]- GABA ^b (GABA _B)	[³⁵ S]TBPS ^c	of [³ H]GABA uptake ^d
GABA	100 ^e	100/		95
baclofen	15	100		
picrotoxin			90 ^e	
cis-1	<10	<10	<5	<5
cis- 2	<10	<10	<5	15
trans-3	<10	<10	<5	<5
trans- 4	43	38	<5	<5

^a GABA_A receptor binding was performed according to the method of Enna and Snyder¹² using [³H]GABA as a ligand. Nonspecific binding was determined by conducting the assay in the presence of 1 mM unlabeled GABA. The results are the means of three experiments, each of which was performed in duplicate. In all cases the standard error of the means was less than 10%. ^bGABA_B receptor binding was performed by using a previously reported assay.¹³ The binding site was defined by incubating rat brain membranes with [3H]GABA and 40 µM isoguvacine to inhibit attachment to $GABA_A$ receptor sites. Baclofen (100 μ M) was used to define nonspecific binding. Values represent the means of three experiments, each of which was performed in duplicate. Standard errors were less than 20%. ^c[³⁵S]TBPS binding was as-sayed according to the method of Squires et al.¹⁸ Nonspecific binding was defined as the amount of radioactivity bound in the presence of 10 μ M unlabeled TBPS. Values represent the means of two experiments, each of which was performed in duplicate. ^d High-affinity [³H]GABA uptake into rat brain synaptosomes was analyzed according to the method of Krogsgaard-Larsen.¹⁶ The values are the means of two experiments. [°]The IC_{50} value for GABA on GABA_A binding is 20 nM. / The IC₅₀ value for GABA on GABA_B binding is 80 nM. ^a The IC₅₀ value for picrotoxin on TBPS binding is 180 nM.

Table II. Effects of Diastereomeri	Table	II.	Effects	of	Diaster	eomeri	ic
------------------------------------	-------	-----	---------	----	---------	--------	----

Decahydroquinoline-5-carboxylic Acids on Hormone-Stimulated Cyclic AMP Formation and Baclofen-Enhanced Cyclic AMP Formation^a

- 01111401011			
compd (100	cAMP forma- tion, % conver- sion	compd (100 µM)	cAMP forma- tion, % conver- sion
no addition	0.16	isoproterenol + trans-3	0.91
isoproterenol	0.84	isoproterenol + trans-4	0.84
baclofen	0.20	ISO^b + baclofen + cis-1	2.59
isoproterenol	2.56	ISO + baclofen + cis-2	2.81
+ baclofen		ISO + baclofen + trans-3	2.63
isoproterenol + cis-1	0.86	ISO + baclofen + trans-4	2.65
isoproterenol + $cis-2$	0.80		

^a Cyclic AMP accumulation in rat brain cerebral cortical slices was analyzed according to the method of Shimizu et al.¹⁴ and cyclic AMP was isolated by using the double-column method of Solomon et al.¹⁵ The results are the means of two experiments, each of which was performed in duplicate. ^b ISO = isoproterenol.

was less than 50%. The results for *cis*-1 and 2 on $GABA_A$ receptors are in accord with previously published results. At these concentrations, GABA displaces 100% of [³H]-GABA from either binding site, whereas the agonist baclofen [3-(4-ClC₆H₄)GABA] is more selective¹³ for the GABA_B site.

A summary of results with 1–4 on hormone-stimulated cyclic AMP formation and baclofen-enhanced cyclic AMP formation is found in Table II. None of the decahydroquinoline diastereomers enhanced either isoproterenol- or

Table III. Effects of Diastereomeric

Decahydroquinoline-5-carboxylic Acids on [³H]Diazepam Binding and GABA-Activated Diazepam Binding in Rat Brain Membranes^a

test compd (100 μM)	[³ H]diazepam, fmol spec bound/mg of protein
[³ H]diazepam	29.3
$[^{3}H]$ diazepam + cis-1	31.9
[³ H]diazepam + cis-2	32.0
$[^{3}H]$ diazepam + trans-3	28.8
$[^{3}H]$ diazepam + trans-4	35.0
[³ H]diazepam + GABA	55.4
$[^{3}H]$ diazepam + GABA + cis-1	55.3
$[^{3}H]$ diazepam + GABA + cis-2	59.4
$[^{3}H]$ diazepam + GABA + trans-3	59.1
$[^{3}H]$ diazepam + GABA + trans-4	65.5

^a [³H]Diazepam binding and GABA-activated diazepam binding were analyzed according to the method of Tallman et al.¹⁷ Nonspecific binding was determined in the presence of 1 μ M unlabeled diazepam. The results are the means of two experiments, each of which was performed in duplicate.

Table IV. Effect of ICV Administration of trans-Decahydroquinolines 3 and 4 on Mice^a

treatment groups	tonic-clonic seizure ^b	duration of seizure, min (mean \pm SEM)
saline	0/6	,
trans-3	/	
100 µg	$5/5^{c}$	26.5 ± 1.4
50 µg	$5/5^{\circ}$	9.5 ± 0.6
$25 \ \mu g$	0/5	
trans-4		
100 µg	$5/5^{c}$	11.7 ± 0.2
50 µg	1/6	0.8 ± 0.6
$25 \mu g$	0'/5	

^a Under halothane anesthesia, saline, trans-3 or trans-4 was injected in a volume of 4 μ L into the left ventricle of the mouse. Animals were placed into a 1-L beaker and observed for seizure activities 2 min post ICV drug injection; behavioral changes were observed for 40 min. ^b Ratio indicates the number of mice showing convulsant activity to the number of mice tested. Seizures were considered present when tonic-clonic convulsions occurred and the mouse fell on its flank. ^c Significantly different from control, p < 0.05 (χ square test).

combined isoproterenol/baclofen-induced cAMP formation.³⁶ When assessed for their effects on [³H]GABA uptake into rat brain slices (Table I), only *cis*-2 exhibited weak inhibitory activity in agreement with previous studies.² Furthermore, at 100 μ M these compounds had no effect on [³H]diazepam binding, GABA-activated diazepam binding (Table III), or [³⁵S]TBPS binding (Table I) in rat brain membranes.

ICV administration of *trans-3* or 4 produced convulsant activity in mice (Table IV). Animals treated with *trans-3* (50 and 100 μ g) and *trans-4* (100 μ g) exhibited tonic-clonic convulsions within 3 min after ICV injection. Unlike *cis-1*,³ neither agent was lethal at these doses. There was no obvious motor impairment during a 40-min postictal observation period.

The effect of diazepam pretreatment in reversing the seizure activities induced by *trans-3* or 4 is shown in Table V. Mice appeared sedated 7 min after the administration (ip) of diazepam (2–10 mg/kg). Five minutes following a 10 mg/kg dose the mice were clearly ataxic. Only at this dose of diazepam was the seizure activity produced by ICV administration of 100 μ g of *trans-4* abolished. Diazepam (10 mg/kg) pretreatment was not effective in abolishing

⁽³⁶⁾ Karbon, E. W.; Enna, S. J. Mol. Pharmacol. 1985, 27, 53-59.

Table V. Effect of Diazepam Pretreatment in Reversing the Seizure Activities Induced by *trans*-Decahydroquinolines 3 and 4^a

treatment groups	tonic-clonic seizure ^b
(1) saline (ip) + saline (ICV)	0/5
(2) saline (ip) + trans-3 (100 μ g, ICV)	5/5°
(3) diazepam $(2 \text{ mg/kg, ip}) + trans-3 (100 \ \mu\text{g, ICV})$	5′/5°
(4) diazepam (5 mg/kg, ip) + $trans$ -3 (100 μ g, ICV)	4/4°
(5) diazepam (10 mg/kg, ip) + trans-3 (50 μ g, ICV)	0/5°
(6) saline (ip) + trans-4 (100 μ g, ICV)	5/5°
(7) diazepam $(2 \text{ mg/kg, ip}) + trans-4 (100 \ \mu\text{g, ICV})$	4/4°
(8) diazepam (5 mg/kg, ip) + $trans-4$ (100 μ g, ICV)	5/5°
(9) diazepam (10 mg/kg, ip) + trans-4 (100 μ g, ICV)	0/6

^aAnimals were pretreated with diazepam (2-10 mg/kg, ip) 10 min prior to the icv administration of various agents. Diazepam (Hoffmann-La Roche Inc.) was administered in a volume of 0.1 mL/10 g of body weight of mice. Animals were observed for convulsant activities for 40 min post ICV drug injection. ^bRatio indicates the number of mice showing the indicated behavior to the total number of mice tested. ^cSignificantly different from the control group, p < 0.05 (χ square test).

seizures produced by 100 μ g of *trans*-3 but did antagonize seizures induced by 50 μ g of *trans*-3.

Discussion

Previously we suggested³ that *cis*-1 may act indirectly as a partial GABA agonist in vivo and that at higher concentrations both cis-1 and 2 exhibit properties of GABA antagonists, but that this effect cannot be explained by an interaction with the classical $GABA_A$ binding site. Results communicated in this article confirm that the cis decahydroquinolines 1 and 2 have a low affinity for either GABA_A or GABA_B binding sites in vitro. Additionally, trans-3 had no measurable affinity for these sites in vitro. Although trans-4 (100 μ M) inhibited [³H]GABA binding to GABA_A and GABA_B receptors in rat brain membranes by 43% and 38%, respectively, this interaction appears weak compared to standard agents on this site.³⁶ Additionally, at 100 μ M none of the four isomers influenced either benzodiazepine binding or GABA-activated benzodiazepine binding, with the latter being a measure of $GABA_{A}$ receptor activity.¹⁷ These compounds had little affinity for GABA transport carriers as no significant inhibition of GABA uptake was observed at 100 μ M. Lack of affinity for the [³⁵S]TBPS binding site¹⁸ suggests that these agents do not interact with the picrotoxinin components of GABA_A receptors in vitro.

Nonetheless, the CNS excitatory effects of cis-1 and 2, like those of picrotoxinin, are completely reversed by valproic acid, a GABA transaminase inhibitor, suggesting that in vivo they may interfere with some aspect of GABA-mediated transmission.³ However, considering the negligible binding activities of the cis analogues as well as *trans*-3 in vitro in light of the demonstrated positive correlation between receptor binding in vitro and activity in vivo of other GABA analogues,³⁷ it does not seem likely that these compounds are acting as antagonists at the GABA receptors that are currently identifiable with binding assays. If the CNS excitatory responses observed after ICV administration are in fact GABA related, it is conceivable that they may be the result of a decrease in GABA release or synthesis or an interaction with a pharmacologically distinct subset of GABA receptors. Alternatively, the brain membrane preparations used in these binding assays may contain altered receptors such that the bulky zwitterionic decahydroquinoline-5carboxylic acids are unable to fit properly although they are capable of binding to GABA receptors in vivo.

Clearly, these isomers have no effect on the ability of baclofen to potentiate isoproterenol-stimulated cyclic AMP formation. It is not likely that these isomers interact with GABA_B receptors in vivo. The finding that diazepam reverses the convulsant activity of both *trans*-4 and *trans*-3 is not necessarily a reflection of GABA antagonist activity in vivo. Of the four diastereomers, *trans*-4 is the only one that inhibits [³H]GABA binding to brain membrane preparations. It is of interest that *trans*-3 and *cis*-1 are the most potent convulsants in this series and that the zwitterionic topography found in *trans*-3 is mimicked in 1b. Future studies will concentrate on investigating the stereoselective CNS effects of amino and carboxylic acid zwitterionic topographies intrinsic to the four decahydroquinoline-5-carboxylic acids.

Experimental Section

Melting points were determined in open capillaries with a Thomas-Hoover Uni-Melt apparatus and are uncorrected. Infrared spectra were recorded with a Beckman Model 4230 spectrophotometer. Nuclear magnetic resonance spectra were recorded with either a Bruker WP-80, HX-90E, or WM-300 MHz spectrophotometer. Me₄Si (CDCl₃, Me₂SO) was used as internal standard. Mass spectra were recorded with a DuPont Model 21-491 mass spectrometer with a Model 21-094 data system. High-resolution mass spectra were obtained with a Kratos MS-30 mass spectrometer. Elemental analyses were performed by Galbraith Laboratories, Inc., Knoxville, TN.

 $(4a\alpha,5\beta,8a\beta)$ -Decahydroquinoline-5-carboxylic Acid (trans-3) Hydrochloride. A solution of 23 (77 mg, 0.24 mmol) in 20 mL of THF/H₂O (1:1) containing 0.020 mL of concentrated HCl was hydrogenated over 25 mg of 10% Pd/C at room temperature and 40 psi for 2 h. After filtration, the solvent was removed under reduced pressure and the residue was dissolved in a minimal amount of MeOH. This solution was passed through a small plug of Celite and concentrated. The residual semisolid was recrystallized from MeOH/Me₂CO, affording 34 mg (45.6%) of trans-3 as white crystals: mp 315-320 °C dec; IR (KBr) 3400-2200, 1720, 1590 cm⁻¹; NMR (D₂O, 300 MHz) δ 1.1-1.9 (m, 11 H), 2.68 (br s, 1 H, 5-H), 2.79 (br dt, 1 H, $J_{ea} \simeq 2.5$ Hz, J_{gem} $\simeq J_{aa} \simeq 12-13$ Hz, 2ax-H), 3.19 (d, 1 H, $J_{gem} \simeq 12.3$ Hz, 2eq-H), 3.39 (br dt, 1 H, $J \simeq 3.4$ and 11.4 Hz, 8a-H) with 4.30 (HOD). Anal. (C₁₀H₁₈ClNO₂) C, H, N, Cl.

 $(4a\alpha,5\alpha,8a\beta)$ -Decahydroquinoline-5-carboxylic Acid (*trans-4*) Hydrochloride. A solution of 19 (375 mg, 1.183 mmol) in 60 mL of THF/H₂O (1:1) containing 0.4 mL of 10% HCl solution was hydrogenated over 125 mg of 10% Pd/C at room temperature and 40 psi for 2 h. After filtration, the solvent was removed under pressure and the residue was dissolved in MeOH. The solution was passed through a small plug of Celite and concentrated. The residual semisolid was recrystallized from MeOH/Et₂O, affording 216 mg (83.2%) of *trans-4* as off-white granules: mp 275-280 °C dec; IR (KBr) 3300-2300, 1730, 1560 cm⁻¹; NMR (D₂O, 300 MHz) δ 1.0-1.8 (m, 11 H), 2.06 (dt, 1 H, $J \simeq 3.4$ and 11.2 Hz, 5-H), 2.6-2.9 (m, 2 H, 8a-H, 2ax-H), 3.20 (br d, 1 H, $J \simeq 12.8$ Hz, 2eq-H), with 6.30 (s, HOD). Anal. (C₁₀H₁₈ClNO₂) C, H, Cl, N.

4,6,7,8-Tetrahydro-2,5(1*H,3H*)-quinolinedione (10). The method of Shono et al.²⁴ was employed, affording 10 in 54% yield as a very lightly colored green-yellow solid: mp 198–200 °C (lit.²³ mp 200–201 °C; lit.²⁴ mp 194–195 °C); IR (KBr) 3200, 3120, 1695, 1635, 820 cm⁻¹; MS, m/e 165 (M⁺).

trans-Hexahydro-2,5(1H,3H)-quinolinedione (11). A solution containing 10 (1.0 g, 6.06 mmol), 10% aqueous KOH (1 mL), and MeOH (100 mL) was hydrogenated over 300 mg of 10% Pd/C at room temperature and 40 psi for 2 h. The solution was acidified to pH 2 with 10% HCl solution, filtered, and concentrated under reduced pressure to yield a solid. CHCl₃ (150 mL)

⁽³⁷⁾ Olsen, R. W.; Ticku, M. K.; Greenlee, D.; Van Ness, P. In "GABA-Neurotransmitters: Pharmacochemical, Biochemical and Pharmacological Aspects"; Krogsgaard-Larson, P., Scheel-Kruger, J., Kofod, H., Eds.; Academic Press: New York, 1979; pp 165-178.

was added and the mixture shaken and passed through a small plug of Celite. The CHCl₃ was removed under reduced pressure, producing a white solid which was washed with Me₂CO to afford 828 mg (81.8%) of a mixture (64:36) of 11 and its cis diastereomer, respectively. Isomer 11 was separated by fractional crystallization (H₂O) affording colorless needles: mp 229–230 °C dec; IR (KBr) 3190, 3060, 1710, 1650, 830 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 1.2–2.7 (m, 11 H), 3.27 (dt, 1 H, $J \simeq 3.3$ and 10.5 Hz, 8a-H), 7.0 (br s, 1 H, NH); MS, m/e 167 (M⁺). Anal. (C₉H₁₃NO₂) C, H, N.

trans-5-(1,3-Dithian-2-ylidene)octahydro-2(1H)quinolinone (13). To an ice-cooled solution of 2-(trimethylsilyl)-1,3-dithiane (1.15 g, 0.006 mol) in dry THF (25 mL) was added n-BuLi [1.55 M in hexane (3.75 mL, 0.006 mol)]. After the mixture was stirred for 1/2 at 0 °C, solid 11 (0.500 g, 0.003 mol) was added. The reaction mixture was allowed to warm to room temperature and stirring was continued for 36 h after which time the mixture was quenched with H_2O (25 mL) and extracted with CHCl₃. The organic phase was washed with brine, dried $(MgSO_4)$, filtered, and concentrated under reduced pressure, affording a solid/oil mixture. This mixture was washed with hexane, affording 672 mg (83.5%) of 13 as white needles (EtOH): mp 222-229 °C dec; IR (KBr) 3180, 3040, 2920, 2850, 1645 cm⁻¹ NMR (CDCl₃, 90 MHz) δ 1.2-2.7 (m, 14 H), 2.7-3.1 [m, 4 H, $2(CH_2S)$], 3.35 (dt, 1 H, J \simeq 3.7 and 10.5 Hz, 8a-H), 5.95 (br s, 1 H, NH); MS, m/e 269 (M⁺). Anal. (C₁₃H₁₉NOS₂) C, H, N, S.

 $(4a\alpha, 5\alpha, 8a\beta)$ -5-(1, 3-Dithian-2-yl)octahydro-2(1H)quinolinone (16). A solution of 13 (925 mg, 3.44 mmol), triethylsilane (1 mL), and trifluoroacetic acid (2.0 mL) in CH₂Cl₂ (10 mL) was stirred at room temperature for 8 days. The reaction mixture was made alkaline with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂. The organic layer was dried (CaSO₄), filtered, and concentrated under reduced pressure, affording 890 mg (95.4%) of 16 as fine white needles (EtOH): mp 222-223 °C; IR (KBr) 3150, 3030, 2900, 1640 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 1.2-2.6 (m, 14 H), 2.7-3.2 [m, 5 H, 8a-H, 2 (CH₂S)], 4.38 (s, 1 H, SCHS), 5.92 (br s, 1 H, NH); MS, m/e 271 (M⁺). Anal. (C₁₃H₂₁NOS₂) C, H, N, S.

Phenylmethyl $(4a\alpha, 5\alpha, 8a\beta)$ -5-(1, 3-Dithian-2-yl)octahydro-1(2H)-quinolinecarboxylate (17). A mixture of 16 (900 mg, 3.32 mmol) and $LiAlH_4$ (505 mg, 13.28 mmol) in 100 mL of dry THF was refluxed under N_2 . After 20 h the reaction mixture was cooled to room temperature, carefully quenched with Na₂S- $O_4 10H_2O$, and filtered. The filtered aluminum salts were washed with hot THF and the combined filtrates were concentrated under reduced pressure to afford 898 mg of a viscous oil containing $(4a\alpha,5\alpha,8a\beta)$ -5-(1,3-dithian-2-yl)decahydroquinoline. This crude compound was taken up in 25 mL of THF to which 15 mL of 10 aqueous KOH solution subsequently was added. Benzyl chloroformate (850 mg, 4.98 mmol) was then added to this biphasic solution which was vigorously stirred for 2 h. The mixture was acidified with 10% HCl, extracted with CH2Cl2, washed with brine, dried (MgSO₄), and concentrated under reduced pressure, affording 2.3 g of a light yellow oil. The oil was chromatographed on silica gel (column) by elution with CHCl₃, yielding 1.14 g (88.1%) of 17 as a viscous, undistillable, colorless oil: IR (Neat) 2930, 2890, 2855, 1690, 750, 695 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 0.8-2.3 (m, 14 H), 2.7-3.0 [m, 4 H, 2(S-CH₂)], 3.1-3.4 (m, 2 H, 2ax-H, 8a-H), 3.73 (observed center) (ddd, 1 H, $J \simeq 3.5$, 6.2 and 13.8 Hz, 2eq-H), 4.36 (s, 1 H, SCHS), 5.12 (s, 2 H, OCH₂), 7.34 (s, 5 H, phenyl); MS, m/e 391 (M⁺). Anal. (C₂₁H₂₉NO₂S₂) C, H, N, S.

Phenylmethyl $(4a\alpha,5\alpha,8a\beta)$ -5-Formyloctahydro-1(2H)quinolinecarboxylate (18). To a vigorously stirred suspension of red HgO (445 mg, 2.046 mmol) and BF₃·Et₂O (290 mg, 2.046 mmol) in 15% aqueous THF (10 mL) was added a solution of 17 (400 mg, 1.023 mmol) in 2 mL of THF. After refluxing for 0.5 h the HgO dissolved and the reaction mixture turned colorless. Refluxing was continued for 24 h during which time a grey precipitate formed. The reaction mixture was cooled to room temperature and Et₂O (10 mL) was added. The coagulated precipitate was triturated and washed with Et₂O, and the combined washings were concentrated to a volume of 5 mL. H₂O (10 mL) was added and the mixture was extracted with CHCl₃, dried (MgSO₄), and concentrated under reduced pressure to afford 290 mg of a colorless oil. The oil was chromatographed on silica gel (column) by elution with CHCl₃, affording 275 mg (89.3%) of 18 as a colorless oil: bp 115 °C (0.01–0.05 mm; micro distillation); IR (neat) 2930, 2855, 2700, 1720, 1690, 745, 690 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 0.8–2.3 (m, 12 H), 3.18 (dt, 1 H, $J \cong 3.2$ and 10.3 Hz, 8a-H), 3.3–3.8 (m, 2 H, NCH₂), 5.13 (s, 2 H, OCH₂), 7.34 (s, 5 H, phenyl), 9.56 (d, 1 H, $J \cong 3.2$ Hz, CHO). Anal. (C₁₇H₂₃NO₃) C, H, N.

 $(4a\alpha, 5\alpha, 8a\beta)$ -Octahydro-1,5(2H)-quinolinedicarboxylic Acid 1-Phenylmethyl Ester (19). To a cooled solution (ice bath) of 18 (175 mg, 0.581 mmol) in Me₂CO (15 mL) was added Jones reagent [diluted to 1.25 M Cr(VI)] dropwise until the orange color of the reagent persisted. After the solution was stirred for an additional 0.5 h, the excess chromic acid was quenched with i-PrOH and the solution decanted. The chromium salts were triturated with Me₂CO (five times) and the combined washings were concentrated under reduced pressure. The residue was taken up in a saturated Na₂CO₃ solution and extracted with Et₂O. The aqueous layer was acidified with diluted H_2SO_4 solution and extracted with CHCl₃. The CHCl₃ layer was dried (MgSO₄) and concentrated under reduced pressure to afford 161 mg of a colorless oil which solidified on standing overnight. Recrystallization (Me₂CO/hexane) yielded 135 mg (73.2%) of 19 as fine colorless plates: mp 124-125 °C; IR (KBr) 3400-2400, 1700, 1680, 740, 695 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 1.0–2.3 (m, 12 H), 3.0–3.5 (m, 2 H, 8a-H, 2ax-H), 3.7 (observed center) (ddd, 1 H, $J \simeq 3.3$, 6.0 and 13.5 Hz, 2eq-H), 5.13 (s, 2 H, OCH₂), 7.34 (s, 5 H, phenyl), 9.0 (br s, 1 H, CO₂H); MS, m/e 317 (M⁺). Anal. (C₁₈H₂₃NO₄) C, H, N.

trans-Octahydro-5-methylene-2(1H)-quinolinone (20). To a suspension of methyltriphenylphosphonium iodide (2.420 g, 5.988 mmol) in 50 mL of THF was added 1.6 M of n-BuLi (3.75 mL, 5.988 mmol). The resulting solution was stirred under N_2 at room temperature for 4 h. Solid 11 (500 mg, 2.994 mmol) was added and the mixture refluxed for 3 h. After the mixture cooled to room temperature, H_2O (25 mL) was added and the solution extracted with Et₂O, dried (MgSO₄), and concentrated under reduced pressure, affording 1.23 g of a yellow solid/oil mixture. Purification by flash chromatography using EtOAc as eluent afforded 264 mg (53.4%) of 20 as white needles $(CHCl_3/hexane)$: mp 154.5-156 °C; IR (KBr) 3190, 3080, 3060, 2940, 2870, 1690, 1660 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 1.0-2.6 (m, 11 H), 2.95 (dt, 1 H, $J \simeq 3.3$ and 10.0 Hz, 8a-H), 4.75 [d, with small (~1 Hz) allylic coupling, 2 H, J = 13.0 Hz, vinyl H], 6.06 (br s, 1 H, NH); MS, m/e 165 (M⁺). Anal. (C₁₀H₁₅NO) C, H, N.

Phenylmethyl trans-Octahydro-5-methylene-1(2H)quinolinecarboxylate (21). A mixture of 20 (260 mg, 1.576 mmol) and LiAlH₄ (240 mg, 6.30 mmol) in 50 mL of dry THF was refluxed for 5 h under N₂. After cooling to room temperature, the reaction mixture was carefully quenched with Na₂SO₄·10H₂O and filtered. The aluminum salts were washed with hot THF and the combined filtrates were concentrated under reduced pressure, affording 240 mg of a solid containing trans-decahydro-5methylenequinoline. This crude compound was dissolved in 10 mL of THF followed by 2 mL of 10% aqueous KOH. Benzyl chloroformate (540 mg, 3.15 mmol) was then added and the resulting biphasic solution was stirred vigorously for 1 h. H₂O (10 mL) was added and the mixture extracted with Et₂O. The organic layer was washed with 10% HCl solution, dried (MgSO₄), and concentrated under reduced pressure to give a colorless oil which was chromatographed on silica gel (column) by elution with CHCl₃, yielding 428 mg (95.3%) of 21 as a colorless oil: IR (Neat) 2940, 2865, 1700, 1650, 700 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 1.1-2.5 (m, 11 H), 3.0-3.5 (m, 2 H, 2ax-H, 8a-H), 3.80 (observed center) (ddd, 1 H, $J \simeq 2.5$, 6.5 and 13.5 Hz, 2eq-H), 4.62 [d, with small $(\sim 1 \text{ Hz})$ allylic coupling, 2 H, $J \simeq 16.5 \text{ Hz}$, vinyl H], 5.13 (s, 2 H, OCH₂), 7.33 (s, 5 H, phenyl); MS, m/e 285 (M⁺). Anal. (C₁₈H₂₃NO₂) C, H, N.

Phenylmethyl $(4a\alpha,5\beta,8a\beta)$ -Octahydro-5-(hydroxymethyl)-1(2H)-quinolinecarboxylate (22). To a cooled (dry ice) solution of 21 (380 mg, 1.33 mmol) in dry THF (20 mL) was added B₂H₆ [0.98 M in THF (2 mL, 1.96 mmol)]. The mixture was allowed to warm to room temperature and stirring was maintained for 1 h after which time 6 N NaOH solution (5 mL) was slowly added. H₂O₂ (30%; 3.5 mL) was added and the resulting solution was stirred vigorously overnight. K₂CO₃ was added to saturate the aqueous phase and the mixture was extracted with Et₂O. The combined Et₂O extracts were dried (MgSO₄) and concentrated under reduced pressure to afford 436 mg of a colorless oil. Purification by flash chromatography using CHCl₃ as eluent gave 400 mg (99%) of **22** as a colorless, viscous oil: IR (neat) 3600–3100, 2930, 2870, 1680, 700 cm⁻¹; NMR (CDCl₃, 90 MHz) δ 1.0–2.2 (m, 12 H), 2.8–4.0 (m, 6 H), 5.12 (s, 2 H, CH₂Ph), 7.34 (s, 5 H, phenyl); MS, m/e calcd (M⁺) 303.1834, obsd 303.1856.

 $(4a\alpha,5\beta,8a\beta)$ -Octahydro-1,5(2H)-quinolinedicarboxylic Acid 1-Phenylmethyl Ester (23). To a biphasic mixture of 22 (103 mg, 0.340 mmol) and NaIO₄ (255 mg, 1.190 mmol)³⁵ in CCl₄ (1.5 mL), CH₃CN (1.5 mL), and H₂O (2.25 mL) was added RuCl₃·3H₂O (2 mg, 2.2 mol %). After the mixture was stirred vigorously for 2 h, CH₂Cl₂ (10 mL) was added, and the solvent layers were separated. The aqueous layer was extracted (three times) with CH₂Cl₂, and the combined organic extracts were dried (MgSO₄) and concentrated. The residue was dissolved in Et₂O, passed through a small plug of Celite, and concentrated under reduced pressure, affording 99 mg of an oil. Purification by preparative TLC (CHCl₃/HOAc, 100:2) produced 77 mg of crude 23 as a viscous oil which was used directly without further purification.

Acknowledgment. FT NMR 300-MHz spectra were produced at The Ohio State University Chemical Instrumentation Center using a Bruker WM-300 spectrometer funded in part by NIH Grant No. 1-S10-RR01458-01A1. Spectra were obtained by Dr. C. E. Cottrell.

Registry No. trans-3, 98761-59-2; trans-3·HCl, 98761-61-6; trans-4, 98761-62-7; trans-4·HCl, 98761-63-8; 10, 5057-12-5; 11, 70075-68-2; 13, 98761-65-0; 16, 98761-66-1; 17, 98761-67-2; 18, 98761-69-4; 19, 98761-64-9; 20, 98761-70-7; 21, 98761-71-8; 22, 98761-72-9; 23, 98761-60-5; I, 77823-89-3; II, 98819-45-5; III, 98819-46-6; IV, 98819-47-7; V, 98761-73-0; VI, 98761-74-1; Ph₃PCHCHO, 2136-75-6; 2-(trimethylsilyl)-1,3-dithiane, 13411-42-2; (4a α , 5 α , 8a α)-5-(1,3-dithian-2-yl)decahydroquinoline, 98761-68-3.


Neuroleptic Activity of Chiral trans-Hexahydro- γ -carbolines[†]

Reinhard Sarges,^{*‡} Harry R. Howard,[‡] Kathy M. Donahue,[‡] Williard M. Welch,[‡] Beryl W. Dominy,[‡] Albert Weissman,[‡] B. Kenneth Koe,[‡] and Jon Bordner[§]

Pfizer Central Research, Pfizer Inc., Groton, Connecticut 06340, and North Carolina State University, Raleigh, North Carolina 27695. Received March 8, 1985


A series of *trans*-8-fluoro-5-(4-fluorophenyl)-2,3,4,4a,5,9b-hexahydro-1*H*-pyrido[4,3-*b*]indoles with various N-2 substituents has been prepared and tested for neuroleptic activity ($[^{3}H]$ spiroperidol binding and amphetamine antagonism). Several members of this series showed exceptional in vivo potency, especially the hydantoin derivatives 27-30. Resolution into the enantiomers showed that neuroleptic activity is associated with the 4aS,9bS absolute configuration. These rigid neuroleptics have been correlated with other rigid neuroleptics [(+)-dexclaunol, Ro 22-1319] and can serve to further define the topography of the dopamine receptor.

Previous work from these laboratories has shown that the tetrahydro- γ -carboline derivative flutroline (1; CP-36,584; 8-fluoro-5-(4-fluorophenyl)-2-[4-hydroxy-4-(4fluorophenyl)buty]-2,3,4,5-tetrahydro-1*H*-pyrido[4,3-*b*]indole) is a potent neuroleptic agent in animal models, apparently due to blockade of dopamine receptors in the central nervous system.¹ Reduction of the 4a,9b double



1 (flutroline)

bond of flutroline with borane resulted in the formation of a 1:1 mixture of two *trans*-hexahydro- γ -carboline diastereomers. These were separated by crystallization and subsequently resolved as the L-phenylalanine esters into their respective enantiomers **2a** to **2d**.² Interestingly, neuroleptic activity appeared to residue exclusively in two of these isomers, **2a** and **2c**, their in vitro activity (inhibition of spiroperidol binding) approaching that of haloperidol (**3**, Table I) and their in vivo activity (amphetamine Table I. Activity of Flutroline and Its Fourtrans-Hexahydro- γ -carboline Reduction Products



		2 a-d			
		inhibn of [³ H]- spiroperidol binding: ^a	antagonism of amphetamine (rat): ^b ED ₅₀ , mg/kg sc		
no.	$[\alpha]^{20}$ _D , deg	IC ₅₀ , nM	1 h	5 h	24 h
2a	+3.1	25	0.21	0.05	0.02
2b	-2.7	350	>10	5.7	>10
2c	+32.2	22	0.05	0.02	0.02
2d	-33.0	1800	>10	18.1	>10
1 (flutroline)		$12 \pm 1 \ (7)$	1.0	0.15	2.2
3 (haloperidol)		9	0.66	0.75	>10
4 (penfluridol)		62	\sim 32	2.4	3.9°

^a IC₅₀ values were determined on rat striatal membrane using 0.5 nM radioligand. Entries are based on one to two determinations. For multiple determinations, mean IC₅₀ \pm SE are given with number of determinations in parentheses. ^b 5 mg/kg ip *d*-amphetamine sulfate was administered to rats at 1, 5, 24 h after test drug (N = 5). ^c The ED₅₀ of 4 at 48 h was ~32 mg/kg. This time course is consistent with the one observed after po dosing of 4 by Janssen et al., *Eur. J. Pharmacol.* 1970, *11*, 139.

antagonism) greatly surpassing that of haloperidol, especially at later time points. These findings made it im-

[†]For simplicity's sake, the common name γ -carboline is used in general throughout this paper instead of 1*H*-pyrido[4,3-*b*]indole. [‡]Pfizer Inc.

[§]North Carolina State University.